Alector Inc
ALEC1.465USD
+0.065+4.64%
Market hours （ET）Quotes delayed by 15 min
157.41MMarket Cap
LossP/E TTM
More Details of Alector Inc Company
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Alector Inc Info
Ticker SymbolALEC
Company nameAlector Inc
IPO dateFeb 07, 2019
CEORosenthal (Arnon)
Number of employees238
Security typeOrdinary Share
Fiscal year-endFeb 07
Address131 Oyster Point Blvd., Suite 600
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone14152315660
Websitehttps://alector.com
Ticker SymbolALEC
IPO dateFeb 07, 2019
CEORosenthal (Arnon)
Company Executives of Alector Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Arnon Rosenthal, Ph.D.
Dr. Arnon Rosenthal, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
5.60M
-1.83%
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
President, Head - Research and Development
President, Head - Research and Development
90.76K
-31.47%
Dr. Kristine Yaffe
Dr. Kristine Yaffe
Independent Director
Independent Director
60.41K
+84.69%
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Director
Director
56.41K
+103.58%
Dr. Paula Hammond, Ph.D.
Dr. Paula Hammond, Ph.D.
Independent Director
Independent Director
39.91K
-25.97%
Mr. Mark Altmeyer
Mr. Mark Altmeyer
Independent Director
Independent Director
39.01K
+278.29%
Mr. Giacomo Salvadore, M.D.
Mr. Giacomo Salvadore, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Louis J. (Lou) Lavigne, Jr.
Mr. Louis J. (Lou) Lavigne, Jr.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Errol De Souza, Ph.D.
Dr. Errol De Souza, Ph.D.
Independent Director
Independent Director
--
--
Dr. Elizabeth A. (Betsy) Garofalo, M.D.
Dr. Elizabeth A. (Betsy) Garofalo, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Arnon Rosenthal, Ph.D.
Dr. Arnon Rosenthal, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
5.60M
-1.83%
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
President, Head - Research and Development
President, Head - Research and Development
90.76K
-31.47%
Dr. Kristine Yaffe
Dr. Kristine Yaffe
Independent Director
Independent Director
60.41K
+84.69%
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Director
Director
56.41K
+103.58%
Dr. Paula Hammond, Ph.D.
Dr. Paula Hammond, Ph.D.
Independent Director
Independent Director
39.91K
-25.97%
Mr. Mark Altmeyer
Mr. Mark Altmeyer
Independent Director
Independent Director
39.01K
+278.29%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.91%
TCG Crossover Management, LLC
9.16%
RTW Investments L.P.
6.40%
Polaris Venture Partners
6.28%
The Vanguard Group, Inc.
5.53%
Other
58.72%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.91%
TCG Crossover Management, LLC
9.16%
RTW Investments L.P.
6.40%
Polaris Venture Partners
6.28%
The Vanguard Group, Inc.
5.53%
Other
58.72%
Shareholder Types
Shareholders
Proportion
Investment Advisor
42.89%
Investment Advisor/Hedge Fund
20.25%
Hedge Fund
9.06%
Venture Capital
7.75%
Individual Investor
6.69%
Corporation
3.25%
Research Firm
2.15%
Pension Fund
0.24%
Bank and Trust
0.09%
Other
7.63%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
349
90.03M
98.61%
+10.00M
2025Q3
362
80.15M
106.47%
+1.69M
2025Q2
360
78.42M
102.48%
-2.24M
2025Q1
365
81.31M
103.38%
-22.06M
2024Q4
366
82.35M
103.74%
-11.52M
2024Q3
362
84.26M
96.78%
-1.24M
2024Q2
361
85.77M
94.54%
-889.02K
2024Q1
362
88.56M
87.42%
+4.86M
2023Q4
367
76.77M
98.07%
+993.74K
2023Q3
372
75.68M
93.10%
+3.65M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
15.00M
14.82%
+608.65K
+4.23%
Jun 30, 2025
Polaris Venture Partners
9.85M
9.74%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
5.99M
5.92%
-65.34K
-1.08%
Jun 30, 2025
Rosenthal (Arnon)
5.53M
5.46%
-51.56K
-0.92%
Sep 02, 2025
BlackRock Institutional Trust Company, N.A.
6.19M
6.11%
-228.85K
-3.57%
Jun 30, 2025
Merck & Co Inc
3.55M
3.5%
--
--
Jun 30, 2025
Acadian Asset Management LLC
2.17M
2.14%
+729.73K
+50.65%
Jun 30, 2025
T. Rowe Price Associates, Inc.
4.83M
4.77%
+4.19M
+652.19%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.34%
iShares Neuroscience and Healthcare ETF
0.17%
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0%
Fidelity MSCI Health Care Index ETF
0%
JPMorgan Fundamental Data Science Small Core ETF
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.34%
iShares Neuroscience and Healthcare ETF
Proportion0.17%
iShares Micro-Cap ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0%
Fidelity MSCI Health Care Index ETF
Proportion0%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Alector Inc?
The top five shareholders of Alector Inc are:
Fidelity Management & Research Company LLC holds 15.00M shares, accounting for 14.82% of the total shares.
Polaris Venture Partners holds 9.85M shares, accounting for 9.74% of the total shares.
The Vanguard Group, Inc. holds 5.99M shares, accounting for 5.92% of the total shares.
Rosenthal (Arnon) holds 5.53M shares, accounting for 5.46% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.19M shares, accounting for 6.11% of the total shares.
Fidelity Management & Research Company LLC holds 15.00M shares, accounting for 14.82% of the total shares.
Polaris Venture Partners holds 9.85M shares, accounting for 9.74% of the total shares.
The Vanguard Group, Inc. holds 5.99M shares, accounting for 5.92% of the total shares.
Rosenthal (Arnon) holds 5.53M shares, accounting for 5.46% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.19M shares, accounting for 6.11% of the total shares.
What are the top three shareholder types of Alector Inc?
The top three shareholder types of Alector Inc are:
Fidelity Management & Research Company LLC
TCG Crossover Management, LLC
RTW Investments L.P.
Fidelity Management & Research Company LLC
TCG Crossover Management, LLC
RTW Investments L.P.
How many institutions hold shares of Alector Inc (ALEC)?
As of 2025Q4, 349 institutions hold shares of Alector Inc, with a combined market value of approximately 90.03M, accounting for 98.61% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -7.86%.
What is the biggest source of revenue for Alector Inc?
In --, the -- business generated the highest revenue for Alector Inc, amounting to -- and accounting for --% of total revenue.
